TL;DR
This study investigated whether performing a second transurethral resection (reTURB) after Bacillus Calmette-Guérin (BCG) immunotherapy, compared to before, impacts oncological outcomes in patients with high-grade T1 bladder cancer. The findings suggest that the timing of reTURB relative to BCG induction does not significantly alter recurrence-free or progression-free survival rates.
What Problem Does This Paper Address?
The standard treatment for high-risk, non-muscle-invasive bladder cancer (NMIBC) involves transurethral resection of bladder tumors (TURB) followed by Bacillus Calmette-Guérin (BCG) immunotherapy. A critical step in managing these cancers is ensuring complete tumor removal and accurate staging, as residual disease or understaging can lead to worse outcomes. Current European Association of Urology (EAU) guidelines recommend a restaging TURB (reTURB) 2-6 weeks after the initial TURB, typically before BCG induction. However, in clinical practice, logistical issues or patient factors sometimes lead to reTURB being performed after the BCG induction course. There was a lack of comparative data on whether this post-BCG reTURB impacts oncological outcomes compared to the standard pre-BCG approach. This study aimed to fill that gap by comparing these two sequences.
Methods
This was a retrospective, multicenter cohort study involving 645 patients with primary T1 high-grade (HG) NMIBC treated between 2001 and 2019 across 12 tertiary care centers. Patients were divided into two groups: those who underwent reTURB before BCG induction (Pre-BCG group) and those who underwent reTURB after BCG induction (Post-BCG group).
To account for potential differences in patient characteristics between the groups, the researchers employed two statistical methods:
- Propensity-Score Matching (PSM): This technique creates matched pairs of patients from each group who have similar baseline characteristics (e.g., age, gender, smoking history, tumor size, presence of muscularis propria). This helps to isolate the effect of the reTURB timing.
- Inverse Probability of Treatment Weighting (IPW): This method assigns weights to patients to create a pseudo-population where the treatment groups are balanced on observed covariates, effectively mimicking a randomized trial.
The primary outcomes assessed were recurrence-free survival (RFS) and progression-free survival (PFS) over a five-year period and the entire observation period.
Datasets
The study utilized data from 645 patients with primary T1HG NMIBC from 12 tertiary care centers. This dataset was collected retrospectively from patient records. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- BCG's Potential Role in Residual Disease: The study observed a statistically significant lower rate of residual disease in the Post-BCG group (30%) compared to the Pre-BCG group (38%). This suggests that BCG immunotherapy itself might have a beneficial effect in reducing or eliminating residual tumor cells, even before a second resection.
- Residual Tumors are a Major Risk Factor: Regardless of reTURB timing, the presence of residual tumors at reTURB was strongly associated with an increased risk of cancer recurrence and progression (2.6- and 3-fold higher, respectively). This reinforces the importance of complete tumor resection.
- Timing May Not Matter for Survival: The core finding is that the timing of reTURB relative to BCG induction does not appear to significantly impact long-term oncological outcomes (RFS and PFS). This challenges the strict adherence to pre-BCG reTURB if logistical issues arise.
Key Results
- No Significant Difference in Survival: After both PSM and IPW analyses, there were no statistically significant differences in five-year RFS or PFS between the Pre-BCG and Post-BCG groups.
- Five-year RFS: 64.7% (Pre-BCG) vs. 69.1% (Post-BCG) (p > 0.05)
- Five-year PFS: 82.7% (Pre-BCG) vs. 83.3% (Post-BCG) (p > 0.05)
- IPW showed Borderline Significance: While not reaching statistical significance in all analyses, IPW showed a trend towards better five-year RFS for the Post-BCG group (68.9% vs. 61.2%, p = 0.063). This suggests a potential, albeit weak, benefit that warrants further investigation.
- Lower Residual Disease in Post-BCG Group: The rate of residual disease detected at reTURB was lower in the Post-BCG group (30%) compared to the Pre-BCG group (38%, p = 0.029).
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: Data was collected retrospectively, which can introduce biases.
- Lack of Randomization: The allocation to Pre-BCG vs. Post-BCG reTURB was based on surgeon discretion and local protocols, not randomization.
- Exclusion of T2 Lesions: Patients with T2 lesions identified at reTURB were excluded as they would not receive BCG therapy, potentially limiting the generalizability of findings for this subgroup.
- Incomplete Data: Details on BCG strain, surgeon experience, and technical aspects of the procedure were not uniformly available or reliable.
- No Central Pathology Review: Specimens were evaluated at participating centers, not centrally.
- Limited CSS Analysis: Cancer-specific death (CSS) events were too few for robust statistical analysis.
Future work could involve prospective, randomized controlled trials to definitively confirm these findings. Further research could also explore the impact of BCG strain and dose on residual disease and outcomes, as well as investigate the optimal timing for reTURB in specific patient subgroups. The potential benefit of BCG in reducing residual disease warrants further investigation.
Summary updated